| 06/03/23 | 10:31:31 | 6 Mar 2023 | | Holding(s) in Company |
| 28/02/23 | 15:55:39 | 28 Feb 2023 | | Posting of Circular and Notice of General Meeting |
| 27/02/23 | 16:30:51 | 27 Feb 2023 | | Director/PDMR Shareholding |
| 24/02/23 | 13:32:25 | 24 Feb 2023 | | Issue of Equity |
| 24/02/23 | 13:32:08 | 24 Feb 2023 | | Agreement with Sebela Pharmaceutical for NTCD-M3 |
| 24/02/23 | 11:00:25 | 24 Feb 2023 | | Price Monitoring Extension |
| 31/01/23 | 11:00:10 | 31 Jan 2023 | | Price Monitoring Extension |
| 26/01/23 | 10:10:17 | 26 Jan 2023 | | Exercise of Options and Total Voting Rights |
| 25/01/23 | 07:00:05 | 25 Jan 2023 | | US Center for Disease Control review paper |
| 22/12/22 | 09:05:23 | 22 Dec 2022 | | Second Price Monitoring Extn |
| 22/12/22 | 09:00:20 | 22 Dec 2022 | | Price Monitoring Extension |
| 22/12/22 | 07:00:03 | 22 Dec 2022 | | Year End Trading Update |
| 07/12/22 | 07:00:08 | 7 Dec 2022 | | FDA/CDC highlight need for infection preventions |
| 07/12/22 | 07:00:02 | 7 Dec 2022 | | XF-73 Nasal final Phase 3 development plans |
| 02/12/22 | 14:48:05 | 2 Dec 2022 | | Director Disclosure |
| 23/11/22 | 07:00:09 | 23 Nov 2022 | | Appointment of Corporate Broker |
| 18/11/22 | 13:16:11 | 18 Nov 2022 | | Director Shareholding Amendment |
| 15/11/22 | 07:00:02 | 15 Nov 2022 | | XF-73 advances to clinically enabling safety study |
| 31/10/22 | 11:06:13 | 31 Oct 2022 | | Second Price Monitoring Extn |
| 31/10/22 | 11:01:06 | 31 Oct 2022 | | Price Monitoring Extension |
| 22/09/22 | 07:00:06 | 22 Sept 2022 | | Notice of R&D Update Meeting |
| 08/09/22 | 07:00:09 | 8 Sept 2022 | | Interim results for six months ended 30 June 2022 |
| 07/09/22 | 07:03:01 | 7 Sept 2022 | | Presenting at HC Wainwright Investment Conference |
| 07/09/22 | 07:01:01 | 7 Sept 2022 | | Positive update from EMA on NTCD-M3 Phase 3 plans |
| 05/09/22 | 14:15:36 | 5 Sept 2022 | | Expiry of Share Options |
| 22/08/22 | 07:00:07 | 22 Aug 2022 | | Notice of Interim Results |
| 28/07/22 | 07:00:06 | 28 Jul 2022 | | Chair’s Investor Update |
| 26/07/22 | 07:00:04 | 26 Jul 2022 | | Publication of new data on NTCD-M3 |
| 19/07/22 | 07:00:06 | 19 Jul 2022 | | Positive update from US FDA on XF-73 Phase 3 |
| 12/07/22 | 07:00:04 | 12 Jul 2022 | | Grant from the Cystic Fibrosis Foundation |
| 07/07/22 | 07:00:07 | 7 Jul 2022 | | Publication of XF-73 drug synergy data |
| 05/07/22 | 07:00:04 | 5 Jul 2022 | | New XF-73 research programme |
| 08/06/22 | 07:00:10 | 8 Jun 2022 | | Grant of share options |
| 27/05/22 | 11:56:18 | 27 May 2022 | | Result of Annual General Meeting & Strategy Update |
| 26/05/22 | 07:00:09 | 26 May 2022 | | Board Changes |
| 12/05/22 | 07:00:03 | 12 May 2022 | | Landmark NTCD-M3 data to be presented at Anaerobe |
| 03/05/22 | 07:00:11 | 3 May 2022 | | Destiny Pharma appoints Dr Yuri Martina as CMO |
| 27/04/22 | 15:34:26 | 27 Apr 2022 | | Posting of Annual Report and Notice of AGM |
| 26/04/22 | 15:30:05 | 26 Apr 2022 | | Director/PDMR Shareholding |
| 12/04/22 | 07:00:04 | 12 Apr 2022 | | Audited results for year ended 31 December 2021 |
| 04/04/22 | 14:45:01 | 4 Apr 2022 | | Notice of Results |
| 04/04/22 | 14:37:08 | 4 Apr 2022 | | Notification of Major Holdings |
| 31/03/22 | 07:00:05 | 31 Mar 2022 | | To present data at ECCMID Congress |
| 28/03/22 | 11:30:08 | 28 Mar 2022 | | Result of General Meeting and Total Voting Rights |
| 25/03/22 | 07:00:06 | 25 Mar 2022 | | Result of Open Offer |
| 22/03/22 | 10:30:02 | 22 Mar 2022 | | Exercise of Options and Total Voting Rights |
| 08/03/22 | 12:30:05 | 8 Mar 2022 | | Fundraising |
| 08/02/22 | 07:00:02 | 8 Feb 2022 | | Positive feedback from EMA on XF-73 Nasal gel Ph 3 |
| 01/02/22 | 16:11:42 | 1 Feb 2022 | | Exercise of Options and Total Voting Rights |
| 01/02/22 | 07:00:02 | 1 Feb 2022 | | Positive data in XF-73 Dermal study with NIAID |
